Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.
Actively Recruiting
Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.
Actively Recruiting
Researchers are evaluating the functional changes in the stomach and esophagus of patients undergoing One Anastomosis Gastric Bypass OAGB. This study aims to assess various risk factors such as age, gender, tobacco and alcohol use, medications, and health conditions for the development of marginal ulcers after surgery, as well as other outcomes related to weight loss and gastrointestinal health. The research is sponsored by Spital Limmattal Schlieren and focuses on patients with obesity and related conditions like GERD and gastric ulcers. Participants will undergo the OAGB procedure performed laparoscopically. The surgery involves dividing the stomach and connecting it to the small bowel at a point about 200 cm from the ligament of Treitz. This creates a new pathway for food to bypass part of the stomach and small intestine. The study tracks patients after surgery to monitor changes and complications over time. Throughout the study, participants will be followed for up to 5 years post-surgery. Researchers will monitor marginal ulcer rates, weight loss percentages, changes in esophageal function, reflux events, and quality of life related to gastrointestinal and obesity issues. Assessments include endoscopy, manometry, impedance pH-metry, and questionnaires to evaluate reflux symptoms and life quality. Safety and long-term effects will be carefully observed to understand the impact of OAGB on stomach and esophagus function.
Actively Recruiting
This research evaluates esophageal motility changes in patients undergoing laparoscopic partial fundoplication 180 anterior or 270 posterior for gastroesophageal reflux disease GERD who have preoperative ineffective esophageal motility IEM. The study is combined retro- and prospective and focuses on whether postoperative motility decreases compared to preoperative levels, based on the hypothesis that motility disorders are caused by reflux. Participants who had or will have partial fundoplication between 2020 and 2023 are assessed for preoperative IEM. Those with IEM are invited to undergo high-resolution manometry 18 to 24 months after surgery to examine postoperative motility. The study also compares other motility disorders and evaluates gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale GSRS before and after surgery. During the study, participants provide consent and undergo high-resolution manometry, an outpatient diagnostic test where a thin catheter measures esophageal pressures during swallowing. The GSRS questionnaire is completed pre- and postoperatively as part of routine care. The primary outcome measures the persistence of IEM one to two years after surgery, with secondary outcomes including other motility disorders and symptom changes. The study duration extends through December 2027.
Actively Recruiting
Researchers are evaluating treatment options for patients aged 70 and older with metastatic non-small cell lung cancer NSCLC who have lower than 50% PD-L1 expression and may be frail or in poor health. The study aims to compare the safety and effectiveness of reduced-dose chemotherapy combined with cemiplimab versus cemiplimab alone. This research addresses a gap in evidence for older and frail patients who often cannot tolerate standard chemotherapy doses well. Participants are randomly assigned to one of two groups one receives reduced-dose platinum-doublet chemotherapy combined with cemiplimab, while the other receives cemiplimab monotherapy. The chemotherapy regimens differ according to cancer histology and are given intravenously every three weeks for four cycles, followed by maintenance cemiplimab treatment for up to two years. Patients whose cancer progresses may switch from monotherapy to the combination treatment if suitable. Throughout the study, participants undergo regular imaging scans to assess tumor response every 6 to 12 weeks, along with quality-of-life questionnaires and geriatric assessments of physical function at set intervals. Researchers will monitor progression-free survival, overall survival, response rates, side effects, and overall treatment utility. The trial includes ongoing safety monitoring and aims to provide evidence to improve treatment strategies for older, vulnerable NSCLC patients.
Actively Recruiting
This research aims to evaluate how esomeprazole, given either as a tablet or dissolved in water, affects acid production in the stomach pouch of patients who have undergone Roux-en-Y gastric bypass surgery for morbid obesity. The study focuses on measuring the acid level pH in the gastric pouch and the concentration of esomeprazole in the blood to understand absorption differences after this type of surgery. Participants will undergo a routine upper endoscopy about one year after their gastric bypass surgery. During this procedure, a wireless pH monitoring device is placed in the stomach pouch to continuously measure acid levels. The next day, participants are randomly assigned to receive a single dose of esomeprazole either as a tablet or as a solution dissolved in water. Blood samples are taken before and after dosing to measure esomeprazole levels, and pH monitoring continues for 48 hours. During the study, participants will be monitored for 48 hours with the wireless pH device recording stomach acidity. Blood samples will be collected at specified times to assess the drug concentration. After 48 hours, the pH device is removed, and any adverse effects are checked before the study ends. The primary measure is the pH level over 48 hours, with secondary focus on esomeprazole blood concentrations two hours after dosing. Participants typically complete the study within two days after the initial endoscopy.
Actively Recruiting
This research aims to understand how thyroidectomy removal of the thyroid gland complications may differ depending on the thyroid hormone levels before surgery in patients with Graves disease or Amiodarone-induced thyrotoxicosis AIT. It focuses on whether patients with different thyroid metabolic statescontrolled normal hormone levels or uncontrolled elevated hormone levelshave similar rates of complications such as nerve damage, hypoparathyroidism, bleeding, or severe heart events during and after surgery. The study is observational and uses data collected in the EUROCRINE registry from multiple centers in Europe. Patients who undergo thyroidectomy for Graves disease or AIT are grouped based on their hormone levels before surgery, using free triiodothyronine fT3 and free thyroxine fT4 tests taken within one week prior to surgery. The study does not alter the surgery or treatment methods. Data are collected prospectively through the EUROCRINE registry and an additional module for study-specific routine data. The study plans to include about 25 centers over two years and will record details such as surgery duration, blood loss, medications, monitoring techniques, hospital stay, and any complications. Participants will provide informed consent, and their usual surgical care is not changed. Researchers will track outcomes from the day of surgery through an average of two years, including complications and recovery. Data include clinical information, operative details, and postoperative follow-up. The study aims to help refine surgical guidelines and determine if waiting for normal thyroid levels before surgery is necessary, potentially speeding up treatment and reducing risks and costs for patients.